PMID- 29095654
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20220114
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 34
IP  - 2
DP  - 2018 Feb
TI  - Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed 
      dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous 
      leukemia in the US.
PG  - 353-360
LID - 10.1080/03007995.2017.1399870 [doi]
AB  - OBJECTIVE: Evaluate the incidence of type 2 diabetes mellitus (T2DM) and 
      hyperlipidemia (HLD) in CML patients initiating therapy with dasatinib or 
      nilotinib. METHODS: Retrospective study using MarketScan claims from January 2006 
      to December 2014. The first analysis evaluated occurrence of T2DM, defined as >/=2 
      claims with a T2DM ICD-9 code or 1 diagnosis claim and an antidiabetic 
      medication. The second analysis evaluated occurrence of HLD, defined as >/=2 claims 
      with an HLD ICD-9 code, or 1 diagnosis claim and an anti-HLD medication. 
      Incidence rates were computed as number of events divided by sum of person years 
      (PY) at risk for all subjects. Multivariate Cox proportional hazards models 
      estimated hazard ratios (HRs) for T2DM or HLD. RESULTS: There were 2004 and 1280 
      patients who met the criteria for the T2DM analysis (n = 1272 dasatinib, n = 732 
      nilotinib) and HLD analysis (n = 845 dasatinib, n = 435 nilotinib). The incidence 
      rate of T2DM was 40.4 per 1000 PY (95% CI: 27.60, 56.98) for nilotinib and 17.6 
      per 1000 PY (95% CI: 11.14, 26.38) for dasatinib. HR for occurrence of T2DM was 
      2.77 (95% CI: 1.58, 4.86), indicating that patients on nilotinib had a 
      significantly higher adjusted risk for incident T2DM. The incidence rate of HLD 
      was 74.6 per 1000 PY (95% CI: 50.70, 105.94) for nilotinib and 46.4 per 1000 PY 
      (95% CI: 33.00, 63.45) for dasatinib. HR for occurrence of HLD was 1.75 (95% CI: 
      1.07, 2.87) indicating that patients on nilotinib had a significantly higher 
      adjusted risk for incident HLD. CONCLUSIONS: Patients receiving nilotinib had 
      significantly higher rates of incident T2DM or HLD than patients on dasatinib.
FAU - Franklin, Meg
AU  - Franklin M
AD  - a Franklin Pharmaceutical Consulting LLC , Rock Hill , SC , USA.
FAU - Burns, Leah
AU  - Burns L
AD  - b Center for Observational Research and Data Sciences , Princeton , NJ , USA.
FAU - Perez, Samuel
AU  - Perez S
AD  - c Mu Sigma , Northbrook , IL , USA.
FAU - Yerragolam, Deepak
AU  - Yerragolam D
AD  - d Mu Sigma Business Solutions , Karnataka , India.
FAU - Makenbaeva, Dinara
AU  - Makenbaeva D
AD  - e Bristol-Myers Squibb Company , Princeton , NJ , USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20171130
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - F41401512X (nilotinib)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Correlation of Data
MH  - *Dasatinib/administration & dosage/adverse effects
MH  - Diabetes Mellitus, Type 2/*epidemiology
MH  - Female
MH  - Humans
MH  - Hyperlipidemias/*epidemiology
MH  - Incidence
MH  - Insurance Claim Review
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects
MH  - *Pyrimidines/administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - United States/epidemiology
OTO - NOTNLM
OT  - CML
OT  - hyperlipidemia
OT  - metabolic outcomes
OT  - type 2 diabetes mellitus
OT  - tyrosine kinase inhibitors
EDAT- 2017/11/03 06:00
MHDA- 2019/04/16 06:00
CRDT- 2017/11/03 06:00
PHST- 2017/11/03 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
PHST- 2017/11/03 06:00 [entrez]
AID - 10.1080/03007995.2017.1399870 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2018 Feb;34(2):353-360. doi: 10.1080/03007995.2017.1399870. 
      Epub 2017 Nov 30.